CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
Celldex Therapeutics (CLDX) stock fell 11% despite positive Phase 3 trial results for Barzolvolimab, its treatment for chronic spontaneous urticaria. H.C. Wainwright raised its price target to $64, citing nearly 90% upside potential. The studies met primary and secondary endpoints, but safety concerns, including two cases of probable Grade 4 anaphylaxis, led to the initial sell-off. Celldex plans to file for FDA approval in 2027.
How this was made
The 30-second read
Why it matters
The Phase 3 data represent the first public disclosure of efficacy outcomes, prompting an analyst target raise and a mixed market reaction.
Market read
Fresh pivotal trial data for a micro‑cap biotech, likely to affect CLDX price and sector sentiment.
What to watch
Potential delay in BLA filing or competitive trials could limit near‑term price gains.
Background
Celldex Therapeutics (CLDX) is a clinical‑stage biotech focused on chronic spontaneous urticaria.
Ticker impact
Celldex Therapeutics reported positive Phase 3 trial results for Barzolvolimab, meeting primary and key secondary endpoints.
Potential rally toward $64 target if market digests efficacy data.
Efficacy exceeds expectations; analyst raised price target 52% and maintained Buy rating.
Market effects
Strong CSU trial results may boost sentiment for biotech firms developing allergy/urticaria therapies.
Limited to U.S. biotech sector; no broader regional effect.
Modest; could influence global investors tracking late‑stage biotech pipelines.
Counterpoint
Safety concerns (Grade 4 anaphylaxis) could trigger regulatory scrutiny and dampen upside.
Key entities
- companyCelldex Therapeutics
Biotech developer of Barzolvolimab for chronic spontaneous urticaria.
- analystH.C. Wainwright
Raised CLDX price target to $64 and maintained Buy rating.
